Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"

Inclusion criteria

• Inclusion Criteria for Sickle Cell Patients
• Adults: \> 15 years and 6 months
• Pediatrics: ≥ 3 years and ≤ 15 years and 6 months
• Known SS or Sβ0 phenotypes
• Inclusion Criteria for Control Patients.
• -Adults: \> 15 years and 6 months /Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-Absence of Hemoglobinopathy 3-Follow-up for one of the following conditions (adults): Evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration
• Follow-up for one of the following conditions (pediatrics): Suspected precocious puberty, growth delay, or neurodevelopmental disorder
• Blood sample planned as part of medical care

Exclusion criteria

• Hemoglobin disorder other than sickle cell disease (Criteria for Sickle Cell Patients)
• Hemoglobinopathies other than sickle cell disease (Criteria for Control Patients)
• Transfusion less than 3 months ago
• Chronic active viral disease: hepatitis B, C, HIV
• Current infections or known inflammatory pathologies
• Known hyper or hypothyroidism or subject treated with levothyroxine
• Active tumor pathology or remission for less than 5 years
• Oral corticosteroid therapy in progress
• Participation in interventional biomedical research
• Opposition to participation in research by the patient if he is an adult, or by one of the two parents if the patient is a minor.
• Non-affiliation to a social security system